Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2019 | Myocardial Infarction | Research article

Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique

Authors: Christine Reichart, Jochen Wöhrle, Sinisa Markovic, Wolfgang Rottbauer, Julia Seeger

Published in: BMC Cardiovascular Disorders | Issue 1/2019

Abstract

Background

Data on bioresorbable vascular scaffolds (BVS) for the treatment of long lesions are limited. We studied the use of BVS-Absorb in routine clinical practice and compared the outcome of long lesions with short lesions. Implantation of drug-eluting scaffolds without PSP-technique (predilation, proper sizing and postdilation) is associated with an increased thrombotic risk. We compared the long-term outcome up to 36 months of patients with short (< 20 mm) and long (≥20 mm) coronary artery lesions after implantation of bioresorbable vascular scaffolds (BVS) via PSP-technique.

Methods

Three hundred twenty-six patients with 424 lesions were enrolled in this prospective study and underwent percutaneous coronary intervention with the Absorb BVS. Clinical follow-up was scheduled after 12, 24 and 36 months. In all lesions the PSP-technique was used. The device oriented composite endpoint (DOCE) was defined as cardiac death, myocardial infarction (MI) not clearly related to a non-target vessel and target lesion revascularization (TLR).

Results

Kaplan-Meier estimates for DOCE after 12 months were 2.63% for short lesions and 8.09% for long lesions (p = 0.0131), 5.51% vs. 11.35% (p = 0.0503) after 24 months and 8.00% vs. 18.00% (p = 0.0264) after 36 months of clinical follow-up. Kaplan-Meier estimates for TLR after 12 months were 1.46% for short and 7.69% for long lesions (p = 0.0012), 2.06% vs. 8.75% after 24 months (p = 0.0027) and 4.96% vs. 9.59% after 36 months of follow-up (p = 0.0109). Scaffold thrombosis rates were low.

Conclusions

In long lesions compared to short ones the bioresorbable scaffold Absorb implanted with the proper PSP technique Absorb has significant higher rates of DOCE.

The Level of Evidence

Is 3 (non-random sample).

Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388(10059):2479–91.CrossRef

Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting Bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373(20).

Wykrzykowska JJ, Kraak RP, Hofma SH, et al. AIDA investigators. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med. 2017;376(24):2319–28.CrossRef

Puricel S, Cuculi F, Weissner M, et al. Bioresorbable coronary scaffold thrombosis. Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors J Am Coll Cardiol. 2016;67(8):921–31.PubMed

Kugler C, Markovic S, Rottbauer W, et al. Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison. Coron Artery Dis. 2017;28(2):120–5.CrossRef

Cortese B, Ielasi A, Moscarella E, et al. RAI investigators. Thirty-day outcomes after unrestricted implantation of Bioresorbable vascular scaffold (from the prospective RAI registry). Am J Cardiol. 2017;119(12):1924–30.CrossRef

Díaz Fernández JF, Camacho Freire SJ, Fernández Guerrero JC, et al. Everolimus drug-eluting stent performance in patients with long coronary lesions: the multicenter Longprime registry. Catheter Cardiovasc Interv. 2018;92(7):E493–501. https://doi.org/10.1002/ccd.27657. Epub 2018 May 18.CrossRefPubMed

Lesiak M, Araszkiewicz A, Grajek S, et al. Long coronary lesions treated with thin strut Bioresorbable polymer drug eluting stent: experience from multicentre randomized CENTURY II study. J Interv Cardiol. 2016;29(1):47–56. https://doi.org/10.1111/joic.12262.CrossRefPubMed

Kang DY, Lee CH, Lee PH, et al. Comparison of resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES VI trial. Coron Artery Dis. 2018. https://doi.org/10.1097/MCA.0000000000000680. [Epub ahead of print].

10.

Patra S, Chakraborty RN, Pande A, et al. Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis. Cardiovasc Revasc Med. 2017;18(3):160–164. https://doi.org/10.1016/j.carrev.2016.12.007. Epub 2016 Dec 15.

11.

Morino Y, Abe M, Morimoto T, et al. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (multicenter CTO registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv. 2011;4(2):213–21.CrossRef

12.

Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guide-lines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the society for cardiac angiography and interventions. J Am Coll Cardiol. 2001;37(8):2215–39.CrossRef

13.

Farooq V, Serruys PW, Heo JH, et al. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model the potential implications for clinical practice. JACC Cardiovasc Interv. 2013;6(5):523–32.CrossRef

14.

Cutlip DE, Windecker S, Mehran R, et al. Academic research consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51.CrossRef

15.

Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43–54.CrossRef

16.

Gao R, Yang Y, Han Y, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease. ABSORB China trial J Am Coll Cardiol. 2015;66(21):2298–309.CrossRef

17.

Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332–42.CrossRef

18.

Costa JR Jr, Abizaid A, Whitbourn R, ABSORB EXTEND investigators et al. three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: final results of the ABSORB EXTEND trial. Catheter Cardiovasc Interv 2018. https://doi.org/10.1002/ccd.27715. [Epub ahead of print].

19.

Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10(10):1144–53.CrossRef

20.

Yamaji K, Räber L, Windecker S. What determines long-term outcomes using fully bioresorbable scaffolds - the device, the operator or the lesion? EuroIntervention. 2017;12(14):1684–7.CrossRef

21.

Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016;387(10018):537–44.CrossRef

22.

Stone GW, Gao R, Kimura T, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387(10025):1277–89.CrossRef

23.

Lipinski MJ, Escarcega RO, Baker NC, et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB Bioresorbable vascular scaffold. A Systematic Review and Meta-Analysis JACC Cardiovasc Interv. 2016;9(1):12–24.CrossRef

24.

Polimeni A, Weissner M, Schochlow K, et al. Incidence, clinical presentation, and predictors of clinical restenosis in coronary Bioresorbable scaffolds. JACC Cardiovasc Interv. 2017;10(18):1819–27. https://doi.org/10.1016/j.jcin.2017.07.034.CrossRefPubMed

25.

Wöhrle J, Nef HM, Naber C, et al. For the GABI-R study group. Predictors of early scaffold thrombosis: results from the multicenter prospective German-Austrian ABSORB RegIstRy. Coron Artery Dis. 2018;29(5):389–96.CrossRef

26.

Tanaka A, Latib A, Kawamoto H, et al. Clinical outcomes of a real world cohort following bioresorbable vascular scaffold implantation utilising an optimized implantation strategy. EuroIntervention. 2017;12(14):1730–7.CrossRef

27.

Sotomi Y, Suwannasom P, Serruys PW, et al. Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. EuroIntervention. 2017;12(14):1747–56.CrossRef

28.

Biscaglia S, Erriquez A, Bernucci D, et al. BRS implantation in long lesions requiring device overlapping: myth or reality? J Thorac Dis. 2017;9(Suppl 9):S914–22. https://doi.org/10.21037/jtd.2017.06.35.CrossRefPubMedPubMedCentral

29.

Polimeni A, Anadol R, Münzel T, et al. Predictors of bioresorbable scaffold failure in STEMI patients at 3 years follow-up. Int J Cardiol. 2018;268:68–74. https://doi.org/10.1016/j.ijcard.2018.04.081..CrossRefPubMed

30.

Regazzoli D, Latib A, Ezhumalai B, et al. Long-term follow-up of BVS from a prospective multicenter registry: impact of a dedicated implantation technique on clinical outcomes. Int J Cardiol. 2018;270:113–7. https://doi.org/10.1016/j.ijcard.2018.06.094. Epub 2018 Jun 25.CrossRefPubMed

31.

Anadol R, Schnitzler K, Lorenz L, et al. Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds. BMC Cardiovasc Disord. 2018;18(1):92. https://doi.org/10.1186/s12872-018-0811-7.CrossRefPubMedPubMedCentral

32.

Haddad K, Tanguay JF, Potter BJ, et al. Longer inflation duration and Predilation-sizing-Postdilation improve Bioresorbable scaffold outcomes in a long-term all-comers Canadian registry. Can J Cardiol. 2018;34(6):752–8. https://doi.org/10.1016/j.cjca.2018.02.030 Epub 2018 Mar 12.CrossRefPubMed

33.

Gori T, Weissner M, Gönner S, et al. Characteristics, predictors, and mechanisms of thrombosis in coronary Bioresorbable scaffolds. Differences Between Early and Late Events JACC Cardiovasc Interv. 2017;10(23):2363–71. https://doi.org/10.1016/j.jcin.2017.08.020.CrossRefPubMed

34.

Biscaglia S, Campo G. Bioresorbable Everolimus-eluting vascular scaffold for long coronary lesions: a subanalysis of the international, multicenter GHOST-EU (gauging coronary healing with bioresorbable scaffolding plaTforms in EUrope) registry. JACC Cardiovasc Interv. 2017;10(12):1274–5. https://doi.org/10.1016/j.jcin.2017.04.001.CrossRefPubMed

35.

Anadol R, Lorenz L, Weissner M, et al. Characteristics and outcome of patients with complex coronary lesions treated with bioresorbable scaffolds: three-year follow-up in a cohort of consecutive patients. EuroIntervention. 2018;14(9):e1011–9. https://doi.org/10.4244/EIJ-D-17-00410.CrossRefPubMed

36.

Sorrentino S, De Rosa S, Ambrosio G, et al. The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment. BMC Cardiovasc Disord. 2015;15:169. https://doi.org/10.1186/s12872-015-0163-5.CrossRefPubMedPubMedCentral

37.

Anadol R, Dimitriadis Z, Polimeni A, et al. Bioresorbable everolimus-eluting vascular scaffold for patients presenting with non STelevation-acute coronary syndrome: a three-years follow-up1. Clin Hemorheol Microcirc. 2018;69(1–2):3–8. https://doi.org/10.3233/CH-189101.CrossRefPubMed

38.

Biscaglia S, Ugo F, Ielasi A, et al. Bioresorbable scaffold vs. second generation drug eluting stent in long coronary lesions requiring overlap: a propensity-matched comparison (the UNDERDOGS study). Int J Cardiol. 2016;208:40–5.CrossRef

39.

Wiebe J, Dörr O, Liebetrau C, et al. Outcome after long-segment stenting with Everolimus-eluting Bioresorbable scaffolds focusing on the concept of overlapping implantation. Rev Esp Cardiol (Engl Ed). 2016;69(12):1144–51. https://doi.org/10.1016/j.rec.2016.08.012. Epub 2016 Oct 27.CrossRef

40.

Geraci S, Kawamoto H, Caramanno G. Et a.. Bioresorbable Everolimus-eluting vascular scaffold for long coronary lesions: a subanalysis of the international, multicenter GHOST-EU registry. JACC Cardiovasc Interv. 2017;10(6):560–8. https://doi.org/10.1016/j.jcin.2016.12.013. Epub 2017 Mar 1.CrossRefPubMed

Title: Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique
Authors: Christine Reichart
Jochen Wöhrle
Sinisa Markovic
Wolfgang Rottbauer
Julia Seeger
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Myocardial Infarction
Thrombosis
Published in: BMC Cardiovascular Disorders / Issue 1/2019
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-018-0994-y

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique

Abstract

Background

Methods

Results

Conclusions

The Level of Evidence

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

The Level of Evidence

Please log in to get access to this content

Other articles of this Issue 1/2019

Factors influencing the accuracy of non-invasive blood pressure measurements in patients admitted for cardiogenic shock

Pulmonary embolism causing atrial fibrillation with slow ventricular response: a case report

Female sex and cardiovascular disease risk in rural Uganda: a cross-sectional, population-based study

Prevalence and risk factors of prolonged corrected QT interval in general Chinese population

Myocardial contrast echocardiography in the diagnosis of postoperative takotsubo myocardiopathy: case report and literature review

Self-management of heart failure in dementia and cognitive impairment: a systematic review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page